TGTX
TG THERAPEUTICS, INC.
Nasdaq: TGTX · New York, NY · Healthcare
$43.37+2.42 (+5.91%)Closed
Market Cap$6.64B
Cash$442.2Mmost recent
Runway74 mo$17.9M Q burn
P/E (TTM)15.7EPS $2.77
52-Wk Range$26.39 – $43.37
Avg Volume2.0M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$43.37+172.8%
Pipeline

Drug candidates sponsored by TG THERAPEUTICS · ClinicalTrials.gov

16 drugs · 38 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 3Obinutuzumab
Chronic Lymphocytic Leukemia
Terminated
2023-02-22past
1
Phase 3Ublituximab
Chronic Lymphocytic Leukemia+16 more
Recruiting
2026-10-31
18
Phase 2Umbralisib
Chronic Lymphocytic Leukemia+4 more
Completed
2022-02-15past
3
Phase 2TGR-1202
Chronic Lymphocytic Leukemia+10 more
Completed
2022-05-25past
3
Phase 1Venetoclax
Chronic Lymphocytic Leukemia+1 more
Terminated
2022-05-26past
1
Phase 1TGR-1202 + brentuximab vedotin
Hodgkin's Lymphoma
Completed
2016-05past
1
Phase 1TGR-1202 + Obinutuzumab + Chlorambucil
Chronic Lymphocytic Leukemia
Completed
2017-11past
1
Phase 1Ublituximab + TGR-1202
Chronic Lymphocytic Leukemia+1 more
Completed
2019-10past
1
Phase 1Cosibelimab
B-cell Non Hodgkin Lymphoma+1 more
Terminated
2022-05-03past
1
Phase 1TG-1701
Non Hodgkin Lymphoma+1 more
Terminated
2024-05-21past
1
Phase 1TG-1801
B-Cell Lymphoma+10 more
Completed
2024-06-12past
2
Phase 1Azercabtagene zapreleucel (azer-cel)
B-cell Mediated Autoimmune Disorders
Recruiting
2027-12-01
1
N/AUnnamed
Relapsing Multiple Sclerosis
Recruiting
2026-06-30
1
N/AUnnamed
Relapsing Multiple Sclerosis+1 more
Recruiting
2032-04-01
1
N/AUnnamed
Multiple Sclerosis
Recruiting
2035-03-31
1
N/AUnnamed
B-cell Mediated Autoimmune Disorders
Not yet recruiting
2039-12-01
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for TGTX. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.